Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-07

Study Completion Date

2029-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies

NCT03157154

Hemophilia

COMPLETED

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

NCT05627375

Venous Thromboembolic Disease

RECRUITING PHASE3

Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage

NCT02091479

Major hæmorrhage

TERMINATED PHASE3

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569

Pulmonary Embolism

RECRUITING PHASE3

Administration of Fibrinogen Concentrate for Refractory Bleeding

NCT05091684

Hematological Patients Bleeding Platelet Refractoriness

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently there are no recommendations on the use of anticoagulant and/or antiplatelet treatment in patients with Rendu-Osler Disease.

The main question this study aims to answer is:

• to better determine which anticoagulant and/or antiplatelet therapy are best tolerated or if they are equivalent in Rendu-Osler disease because this type of treatment is often used in urgent and/or vital situations.

Participants will have a 2-year follow-up with biological monitoring of ferritin and hemoglobin level and ESS (Epistaxis Severity Score) and QoL-HHT (Quality of Life Hereditary Hemorrhagic Telangiectasia) questionnaires.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Hemorrhagic Telangiectasia Rendu Osler Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

cohort study

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort study

a single arm, the anticoagulant and/or antiplatelet treatment is not conditioned by the study

Group Type OTHER

monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease

Intervention Type OTHER

Monitoring:

* hemoglobin and ferritin levels
* transfusion or intravenous iron
* hospitalization for bleeding or thrombose
* digestive bleeding and/or another haemorrhagic accident
* severity of epistaxis
* quality of life

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease

Monitoring:

* hemoglobin and ferritin levels
* transfusion or intravenous iron
* hospitalization for bleeding or thrombose
* digestive bleeding and/or another haemorrhagic accident
* severity of epistaxis
* quality of life

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
* Age \> 18 years old
* Patient able to understand and agree to participate in the study
* Affiliation to a social security system

Exclusion Criteria

* Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months
* Refusal to participate
* Pregnant woman or who are breast feeding
* Patients under maintenance of justice, wardship or legal guardianship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No